Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
reports
Neurosense Therapeutics Ltd. (NRSN) Stock Price & Analysis
17 Followers
NRSN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.08 - $4.47
Previous Close$1.6
Volume43.15K
Average Volume (3M)52.86K
Market Cap
$18.87M
Enterprise Value$15.43M
Total Cash (Recent Filing)$3.58M
Total Debt (Recent Filing)$147.00K
Price to Earnings (P/E)-1.5
Beta0.63
Next Earnings
May 30, 2023EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding11,781,963
10 Day Avg. Volume50,473
30 Day Avg. Volume52,864
Standard Deviation0.46
R-Squared0.01
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)3.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit200.38
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$7.00Price Target Upside357.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Neurosense Therapeutics Ltd. News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRSN FAQ
What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $1.07 and its highest was $4.47 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
Neurosense Therapeutics Ltd.’s upcoming earnings report date is May 30, 2023 which is yesterday.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Neurosense Therapeutics Ltd. released its earnings results on Mar 22, 2023. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.01.
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate is -$0.29.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 11,790,963 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Neurosense Therapeutics Ltd. reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -4.624%.
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Currently, no hedge funds are holding shares in NRSN
---
Neurosense Therapeutics Ltd. Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
---
---